{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:18:58Z","timestamp":1785449938328,"version":"3.56.0"},"reference-count":37,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: This prospective, real-world study, designed by the Greek Research Alliance for Studying headache and Pain (GRASP), primarily aimed to examine whether a single administration of eptinezumab 100 mg can provide early therapeutic benefits over weeks 1\u20134 in preventing high-frequency chronic migraine (HFCM). Methods: We enrolled adults with HFCM (&gt;23 monthly headache days\u2014MHD) who had failed at least three preventive therapies and received a single infusion of 100 mg IV eptinezumab. Its efficacy was assessed using daily headache diaries over weeks 1\u20134 and at week 12, as well as with the Patients\u2019 Global Impression of Change (PGIC) scale at week 4. Primary outcomes included \u226550% reduction in monthly headache days (MHD) through week 4 and early response at week 1. Secondary outcomes included changes in migraine severity, acute medication use, and incidence of most bothersome symptoms (MBS) accompanying headache. Results: A total of 39 HFCM patients were analyzed. Their mean age was 48.1 years, and most were female. More than half (n = 22; 56%) were fast-responders, showing &gt;50% reduction in MHD at week 1. Early 50% response rates at week 1 favored CGRP-na\u00efve patients, compared to prior non-responders. Likewise, significant improvement was observed early across all other efficacy domains through week 4, with sustained benefits through month 3. MBS, like photophobia and nausea, decreased notably, while osmophobia and allodynia improved less over weeks 1\u20134, post-eptinezumab. At week 4, 64.1% of patients reported meaningful overall improvement on PGIC. Conclusions: Eptinezumab rapidly prevented HFCM with clinically meaningful benefits seen early at week 1. Patients experienced sustained improvement in all measured clinical domains through week 4 and onward to month 3.<\/jats:p>","DOI":"10.3390\/jcm14248793","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:30:17Z","timestamp":1765528217000},"page":"8793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-7114","authenticated-orcid":false,"given":"Andreas A.","family":"Argyriou","sequence":"first","affiliation":[{"name":"Headache Outpatient Clinic, Department of Neurology, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-0076","authenticated-orcid":false,"given":"Emmanouil V.","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"General Clinic Thessaloniki, 54645 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-5846","authenticated-orcid":false,"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, \u2018Attikon\u2019 University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Foska","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, \u2018Attikon\u2019 University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-5057","authenticated-orcid":false,"given":"Dimitrios","family":"Rikos","sequence":"additional","affiliation":[{"name":"404 Military Hospital, 41222 Larisa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Soldatos","sequence":"additional","affiliation":[{"name":"Independent Researcher, 24100 Kalamata, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-7898","authenticated-orcid":false,"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[{"name":"Glyfada Headache Clinic, 16675 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/head.14259","article-title":"Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/03331024221110102","article-title":"Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process","volume":"42","author":"Steiner","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","article-title":"Risk factors for migraine disease progression: A narrative review for a patient-centered approach","volume":"270","author":"Lipton","year":"2023","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Argyriou, A.A., Dermitzakis, E.V., Rikos, D., Xiromerisiou, G., Soldatos, P., Litsardopoulos, P., and Vikelis, M. (2024). Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine. Toxins, 16.","DOI":"10.3390\/toxins16020106"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mungoven, T.J., Henderson, L.A., and Meylakh, N. (2021). Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Front. Pain Res., 2.","DOI":"10.3389\/fpain.2021.705276"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/JPR.S329280","article-title":"Central Sensitization in Migraine: A Narrative Review","volume":"15","author":"Suzuki","year":"2022","journal-title":"J. Pain Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Argyriou, A.A., Dermitzakis, E.V., Chondrogianni, M., Foska, A., Rikos, D., Xiromerisiou, G., Soldatos, P., Litsardopoulos, P., and Vikelis, M. (2025). OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group. Toxins, 17.","DOI":"10.3390\/toxins17110547"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/head.14103","article-title":"Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study","volume":"61","author":"Buse","year":"2021","journal-title":"Headache"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13561-023-00459-2","article-title":"Economic burden of chronic migraine in OECD countries: A systematic review","volume":"13","author":"Eltrafi","year":"2023","journal-title":"Health Econ. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/head.13688","article-title":"The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort","volume":"60","author":"Schwedt","year":"2020","journal-title":"Headache"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/head.14383","article-title":"The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition","volume":"62","author":"May","year":"2022","journal-title":"Headache"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/1871527319666200618144637","article-title":"The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms","volume":"19","year":"2020","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/03331024221111526","article-title":"Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine","volume":"42","author":"Iannone","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis","volume":"209","author":"Soni","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/AJP.0000000000001136","article-title":"Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis","volume":"39","author":"Sun","year":"2023","journal-title":"Clin. J. Pain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737175.2025.2461766","article-title":"Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis","volume":"25","author":"Vikelis","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Irimia, P., Santos-Lasaosa, S., Pozo-Rosich, P., Leira, R., Pascual, J., L\u00e1inez, J.M., and L\u00e1inez, J.M. (2024). Eptinezumab for the preventive treatment of episodic and chronic migraine: A narrative review. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1355877"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide","volume":"374","author":"Raport","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","volume":"8","author":"Baker","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/14712598.2021.1931678","article-title":"Eptinezumab for the treatment of migraine","volume":"21","author":"Spuntarelli","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/head.14007","article-title":"Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of Intravenous Eptinezumab vs. Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ailani, J., McAllister, P., Winner, P.K., Chakhava, G., Josiassen, M.K., Lindsten, A., Sperling, B., Ettrup, A., and Cady, R. (2022). Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: Results from the randomized RELIEF trial. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02714-1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","article-title":"Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design","volume":"18","author":"Serrano","year":"2017","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_29","unstructured":"European Medicines Agency (2025, October 20). Summary of Product Characteristics: Eptinezumab (VYEPTI). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyepti-epar-product-information_en.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Villar-Martinez, M.D., and Goadsby, P.J. (2022). Pathophysiology and Therapy of Associated Features of Migraine. Cells, 11.","DOI":"10.3390\/cells11172767"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dermitzakis, E.V., Vikelis, M., Xiromerisiou, G., Rallis, D., Soldatos, P., Litsardopoulos, P., Rikos, D., and Argyriou, A.A. (2024). Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020386"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J. Manip. Physiol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/TCRM.S263824","article-title":"Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection\u2014A Narrative Review","volume":"19","author":"Altamura","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103531","DOI":"10.1016\/j.nicl.2023.103531","article-title":"Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study","volume":"40","author":"Szabo","year":"2023","journal-title":"Neuroimage Clin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/14737175.2020.1770084","article-title":"Medication overuse headache: An overview of clinical aspects, mechanisms, and treatments","volume":"20","author":"Krymchantowski","year":"2020","journal-title":"Expert. Rev. Neurother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:53:12Z","timestamp":1765529592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":37,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248793"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248793","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}